Sector News

Sellas snags Nasdaq listing in reverse merger with Galena

August 9, 2017
Life sciences

Sellas Life Sciences has snagged itself a Nasdaq listing by merging with Galena Biopharma. The deal gives Sellas a route to public investors as it seeks to guide its Wilms tumor 1 (WT1)-targeting drug through phase 3 trials in acute myeloid leukemia (AML) and mesothelioma.

New York, N.Y.-based Sellas will be the dominant partner in the combined company, about a third of which will be owned by Galena shareholders. The investors who hung on to stakes in Galena as its downward spiral turned it into a penny stock now get to roll the dice on another cancer vaccine, Sellas’ galinpepimut-S.

The candidate is set to enter phase 3 after coming through mid-phase trials in AML and mesothelioma. For Sellas, the nub of the deal is a Nasdaq listing that can help it fund its R&D ambitions. But its CEO Angelos Stergiou, M.D., Sc.D., also nodded to the assets it will acquire in the deal.

“NeuVax strengthens our platform and may provide important value inflections as the clinical trials progress,” Stergiou said in a statement.

The transaction brings the prolonged death throes of NeuVax-developer Galena to an end, while continuing Sellas’ pivot. Sellas was once a Swiss-Greek biotech best known for striking—and quickly being booted from—an alliance with China’s Fochon Pharmaceutical. But in recent years it has repositioned itself as a global cancer vaccine player by inking a deal with Memorial Sloan Kettering Cancer Center and moving its center of gravity from Europe to New York and Bermuda.
Sellas quietly made the transition, without publicly disclosing financing rounds, with the support of Equilibria Capital, its largest shareholder. Now, it has put itself in the glare of public markets as it seeks to buck the trend in cancer vaccine trials and deliver positive phase 3 data.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach